Dengue virus envelope protein domain I/II hinge: a key target for dengue virus vaccine design? (Q43038900)

12 November 2017

0 references

Dengue virus envelope protein domain I/II hinge: a key target for dengue virus vaccine design? (English)

1 reference

12 November 2017

0 references

0 references

1 reference

2

Ralph S Baric

1 reference

12 November 2017

Douglas G Widman

1

1 reference

12 November 2017

publication date

24 September 2014

1 reference

Expert Review of Vaccines

12 November 2017

published in

1 reference

12 November 2017

volume

14

1 reference

12 November 2017

issue

1

1 reference

12 November 2017

page(s)

5-8

1 reference

Protective efficacy of the recombinant, live-attenuated, CYD tetravalent dengue vaccine in Thai schoolchildren: a randomised, controlled phase 2b trial

12 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.961431

Safety and immunogenicity of a tetravalent dengue vaccine in healthy children aged 2-11 years in Malaysia: a randomized, placebo-controlled, Phase III study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.961431

Mechanism and significance of cell type-dependent neutralization of flaviviruses

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.961431

Persistence of Th1/Tc1 responses one year after tetravalent dengue vaccination in adults and adolescents in Singapore

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.961431

Live attenuated chimeric yellow fever dengue type 2 (ChimeriVax-DEN2) vaccine: Phase I clinical trial for safety and immunogenicity: effect of yellow fever pre-immunity in induction of cross neutralizing antibody responses to all 4 dengue serotypes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.961431

Live-attenuated, tetravalent dengue vaccine in children, adolescents and adults in a dengue endemic country: randomized controlled phase I trial in the Philippines

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.961431

Antibody-mediated neutralization of flaviviruses: a reductionist view

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.961431

Dengue virus neutralization by human immune sera: Role of envelope protein domain III-reactive antibody

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.961431

Identification of human neutralizing antibodies that bind to complex epitopes on dengue virions

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.961431

Human monoclonal antibodies derived from memory B cells following live attenuated dengue virus vaccination or natural infection exhibit similar characteristics

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.961431

Development and characterization of a reverse genetic system for studying dengue virus serotype 3 strain variation and neutralization

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.961431

Dengue virus envelope protein domain I/II hinge determines long-lived serotype-specific dengue immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.961431

The type-specific neutralizing antibody response elicited by a dengue vaccine candidate is focused on two amino acids of the envelope protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.961431

Binding of a neutralizing antibody to dengue virus alters the arrangement of surface glycoproteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.961431

Molecular organization of a recombinant subviral particle from tick-borne encephalitis virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.961431

Safety and immunogenicity of a recombinant live attenuated tetravalent dengue vaccine (DENVax) in flavivirus-naive healthy adults in Colombia: a randomised, placebo-controlled, phase 1 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.961431

Dengue human infection model: introduction

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.961431

10.1586/14760584.2015.961431

21 January 2018

Identifiers

DOI

1 reference

release_n3u6up7tszav3gti4fpdedss2a

12 November 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/n3u6up7tszav3gti4fpdedss2a

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference